Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

By afschroeder • November 23, 2025

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani A, Yazici A, Lerang K, Troldborg A, Ajeganova S, Popkova TV, Svenungsson E, Pantazis N, Tektonidou MG; SURF-SLE and APS collaborators. Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries. Lancet Rheumatol. 2025 Nov 19:S2665-9913(25)00257-7. doi: 10.1016/S2665-9913(25)00257-7. Epub ahead of print. PMID: 41274305.

Tags: Harbor UCLA, Publications, Rheumatology

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Shared decision making and decision aids in the management of kidney disease and renal replacement treatment options

Zisman-Ilani Y, Rhee CM, Ammary FA, Kalantar-Zadeh K. Shared decision making and decision aids in the management of kidney disease and renal replacement treatment options.[...]

Population health management of diabetic kidney disease in Los Angeles county municipal health system

Kalantar-Zadeh K, Friedman TC, Jafari G, Ghaffari A, Khine A, Nicholas SB, Rhee CM, Dhamija R, Raff EA. Population health management of diabetic kidney disease[...]